Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
- Conditions
- Impaired Glucose Tolerance
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 17
- Registration Number
- NCT01468376
- Locations
- 🇺🇸
Staywell Research LLC, Northridge, California, United States
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Afexa Life Sciences Inc
- Registration Number
- NCT01456182
- Locations
- 🇺🇸
Saint Jospeh Mercy Health System, Ann Arbor, Michigan, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸Cancer Center of the Carolinas, Greenville, South Carolina, United States
A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
- Conditions
- Upper Respiratory Tract Infections
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 293
- Registration Number
- NCT00965822
- Locations
- 🇨🇦
Alberta Health Services, Edmonton, Alberta, Canada
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada
LIP-01 in Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00966225
- Locations
- 🇺🇸
Medicus Research, LLC, Northridge, California, United States
🇨🇦The Northern Alberta Clinical Trials and Research Centre, Edmonton, Alberta, Canada
A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2010-10-11
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00726401
- Locations
- 🇨🇦
Capital Health, Edmonton, Alberta, Canada
🇨🇦McMaster University Medical Centre, Hamilton, Ontario, Canada
🇨🇦Melimar Allergy Laboratory, Toronto, Ontario, Canada